BCA
BMY.RT

Bray Capital Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bray Capital Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,891
Closed -$1K – 274
2020
Q4 		$1K Hold
1,891
– – ﹤0.01% 265
2020
Q3 		$4K Hold
1,891
– – ﹤0.01% 249
2020
Q2 		$7K Hold
1,891
– – ﹤0.01% 242
2020
Q1 		$7K Hold
1,891
– – ﹤0.01% 245
2019
Q4 		$6K Buy
+1,891
New +$4.92K ﹤0.01% 254

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Bray Capital Advisors's BMY.RT Position: Q1 2021 in Review

Bray Capital Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,891 shares — an estimated $1K sold.

Bray Capital Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $7K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Bray Capital Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Bray Capital Advisors sold 1,891 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
  • Bray Capital Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Bray Capital Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $7K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Bray Capital Advisors's 13F filing for Q1 2021, filed 3 May 2021.